-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師總結如下:Corteva公佈了強勁的2026年第一季業績,營運每股盈餘(EPS)為1.50美元,遠超市場普遍預期的1.18美元(年成長33%),淨銷售額為49億美元(年成長11%),超出預期2.7億美元。儘管農業環境充滿挑戰,有機銷售額仍年增7%,反映出市場對差異化技術產品的廣泛需求。強勁的業績表現顯示管理階層有能力從自身優勢出發執行分拆策略,全球銷售成長6%也反映了農民對先進解決方案的持續接受。管理層維持了2026年業績指引,預計營運EBITDA為40億至42億美元,營運每股收益為3.45至3.70美元,併計劃於2026年第四季完成分拆。種子業務板塊表現優異,營業 EBITDA 利潤率達到 34.2%(同比增長 310 個基點),而作物保護業務板塊保持了強勁的增長勢頭,利潤率達到 23.1%(同比增長 101 個基點),這進一步印證了我們的觀點,即這兩個業務板塊中都已做好準備。
Related Articles
Simcere Pharmaceutical Receives Chinese Regulatory Approval to Begin Trials of Tumor Drug
Simcere Pharmaceutical (HKG:2096) received Chinese regulatory approval to begin clinical trials of SIM0613, according to a Hong Kong bourse filing Wednesday.The injection is intended to treat advanced solid tumors and is licensed to Ipsen Pharma in regions outside Greater China.
Meitu Records 30% Rise in Paying Subscribers
Meitu (HKG:1357) said the number of paying subscribers using its platform grew 30% year on year to 17.90 million as of end March, according to a Hong Kong bourse filing Wednesday.Paying subscribers for the company's productivity tools grew 53% to 2.34 million, while leisure app subscribers increased 27% to 15.56 million, the firm said.The company's core revenue grew 34.3% year on year to 852 million yuan, while other businesses remained "stable overall."The company's annual recurring revenue for AI-driven productivity apps stood at 580 million yuan as of March, a 56% increase from a year earlier.
Yidu Tech Unit Wins SG$2.3 Million Singapore Healthcare Project
Yidu Tech (HKG:2158) said its subsidiary EVYD Research Private Limited won a contract from Singapore Health Services for the implementation and support of Dr Buddy, according to a Wednesday Hong Kong bourse filing.The total project amount is about SG$2.3 million.